GlaucomaNCT07771699
Cross-modal Neuromodulation to Improve Balance and Cognition in Older Adults With Glaucoma: A Randomized Trial of Cerebellar Transcranial Electrical Stimulation
A study testing transcranial electrial stimulation in people with Glaucoma, run by The Hong Kong Polytechnic University at 1 site in Hong Kong.
Trial summary
The goal of this clinical trial is to use different tES techniques to constantly stimulate the cerebellum in older glaucoma patients. The main questions aim to answer : 1. If the different types of tES targeting the cerebellum can modulate glaucoma patients' balance function and visual-cognitive function? 2. Read more about this study
- Who is it for?
- Ages 55 years and older
- Conditions the study is for
- Glaucoma
- What is being tested?
- transcranial electrial stimulation
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 36 participants
- Where
- 1 siteHong Kong
- Study dates
- 1 Jul 2026to 1 Nov 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age over 55 years old;
- Diagnosis of primary open-angle or normal-tension glaucoma with relative scotoma in both eyes;
- Humphrey Field Analyzer visual field loss (mean deviation of ≤- 6 dB) using the 24-2 testing protocol for both eyes;
- Best-corrected distance visual acuity of 6/12 (equivalent to 0.3 logMAR) or better;
- Cognitive functional score of 22 or above in the Montreal Cognitive Assessment -Hong Kong version (HK-MoCA).
- Only the right-handed population will be recruited (screening by the Edinburgh Handedness Inventory).
Who cannot join
- Have musculoskeletal disorders or neurological diseases that can affect the balance or nervous system.
- Ocular diseases other than glaucoma (e.g., age-related macular degeneration, diabetic retinopathy, moderate to severe cataract) or severe hearing impairment (to ensure that participants can hear the instructions clearly during assessments and training)
- Have any contraindications for tES
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Hong Kong1 site, 1 recruiting
- Recruiting
Hong Kong Polytechnic University
Kowloon, Hong Kong, 000000
Yihong PENG, phd student, +852-53937970, 22117438r@connect.polyu.hk
Allen Ming Yan Cheong, PhD
About this study
The goal of this clinical trial is to use different tES techniques to constantly stimulate the cerebellum in older glaucoma patients. The main questions aim to answer :
- If the different types of tES targeting the cerebellum can modulate glaucoma patients' balance function and visual-cognitive function?
- Which tES techniques among the two types can benefit most?
Participants will be required to receive the stimulation 15 times (3 sessions, 5 continuous days/session, 1-week interval between each session), and complete the balance and visual-cognitive function outcome measurements before and after each session.
Read the detailed description
Previous research on tES has primarily focused on the effects of different brain cortex stimulation on balance and visual cognitive functions in healthy adults. However, there is a scarcity of research examining the combined effects of these techniques on the cerebellum in visually impaired adults, especially those with glaucoma. Given the cerebellum's crucial role in maintaining balance and cognitive function in glaucoma patients, as evidenced by the latest research, it is essential to determine whether non-invasive cerebellar stimulation can simultaneously improve balance and visual cognitive functions in these patients. Meanwhile, most previous studies only focused on the short-term effects of stimulation, while potential long-term benefits remained unexplored. Our study aims to investigate the long-term effects of two types of tES stimulation on the cerebellum in adults with glaucoma. This research not only aims to fill existing gaps in the literature but also has the potential to develop new intervention strategies to improve functioning in older adults, ultimately enhancing their quality of life.
This study employs a within-subject, sham-controlled, cross-over design. The participants will receive constant tDCS, tACS, and sham stimulation in counterbalanced order. The participants will have three sessions (each session will include five consecutive training sessions) with outcome measurements at six time points. These assessments consist of a baseline test (T1), a test after completing the first session (T2), a test after the first interval week (T3), a test after completing the second session (T4), a test after the second interval week (T5), and a test after completing the third session (T6). The total time will be five weeks.
The outcome measurements will include dynamic balance tests: narrow path walking test and miniBEST test; static balance test: Sensory Organization Test; and two visual cognitive function tests: Reaction Time Test and the Useful Field of View test.
For statistical analysis, IBM SPSS Statistics version 23.0 will be utilized. The Shapiro-Wilk test will be employed to assess the normality of the data distribution. For skewed numerical data, the appropriate transformations will be used to make the data meet the normality assumption. The differences in baseline performance among tACS, tDCS, and sham stimulation were analyzed using repeated-measures ANOVA. To compare the differences between changes in primary and secondary outcomes among baseline and post-intervention time points, the repeated-measures ANOVA will be performed with interventions (tACS, tDCS, and sham) as a within-group factor. Changes in the values will be calculated by subtracting baseline values from the post-intervention values. Paired t-statistics will be obtained to compare the changes in outcome data (subtract baseline from post-intervention) between the interventions (tACS versus tDCS, tACS versus sham, and tDCS versus sham). Post-hoc pairwise comparisons will be performed using Bonferroni corrections. The level of statistical significance is set at p < 0.05.
- Conditions
- Glaucoma
- Being tested
- transcranial electrial stimulation
- Keywords
- balance, glaucoma, visual attention, transcranial electrical stimulation
- Medical subject headings
- Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
transcranial electrial stimulationOther
This intervention is uniquely designed to enhance balance function in patients with glaucoma using non-invasive cerebellar Transcranial Electrical Stimulation (tES), encompassing both transcranial Direct Current Stimulation (tDCS) and transcranial Alternating Current Stimulation (tACS). Glaucoma-induced visual field loss disrupts the visual feedback critical for postural control, forcing patients to rely heavily on sensory re-weighting (integrating vestibular and proprioceptive inputs). The cerebellum is the central hub for this multi-sensory integration and motor adaptation. By modulating cerebellar excitability and neural oscillations, this intervention aims to facilitate sensory re-weighting, optimize vestibular-ocular/spinal reflexes, and ultimately improve dynamic and static balance.
| Study group | Role | What they receive |
|---|---|---|
| tDCS | Experimental | The tDCS stimulation session will be performed over five consecutive days. The tDCS protocol used in this study will involve the application of a low direct current of 2 mA for 20 minutes using a Nurostym tES device (Neuro Device Group SA, Poland). It begins with a 30-second ramp-up period and employs two 5 cm × 5 cm electrodes that are housed in saline-soaked sponges. The anode and the cathode electrodes will be placed bilaterally over the cerebellum (1 cm below the inion of the occipital bone) and the right shoulder, respectively. This electrode montage is based on previous studies and is designed to target cerebellar regions implicated in balance and motor control. Receives: Other: transcranial electrial stimulation |
| tACS | Experimental | The tACS stimulation session will be five consecutive days. tACS protocol used in the study will be delivered using the Neurostym tES device (Neuro Device Group SA, Poland) with two 5 × 5 cm electrodes. The anode and the cathode electrodes will be placed bilaterally over the cerebellum (1 cm below the inion of the occipital bone) and the right shoulder, respectively. The tACS will be administered at a current of 2 mA with a stimulation frequency of 50 Hz. There will be a 30-second ramp-up and ramp-down period to minimize discomfort at the onset and offset of stimulation. Receives: Other: transcranial electrial stimulation |
| Sham | Sham comparator | The sham protocol will mimic the same electrode placement as the other experimental group setting to maintain blinding.
During sham stimulation, the stimulator will deliver 2 mA current for the first 30 seconds, after which the current will be turned off for the remainder of the session. To further enhance blinding, the current will be reactivated at 2 mA for the final 30 seconds of the stimulation and then gradually taper off thereafter. The total duration of the sham stimulation will match that of the active stimulation protocols (20 minutes). Each stimulation session will be five consecutive days. Receives: Other: transcranial electrial stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dynamic Balance Performance-The dual task Narrow Path Walking Test
The Narrow Path Walking Test (NPWT) is a modified version of the Time Up and Go Test (TUGT) that assesses dynamic balance function during gait in a more challenging environment. In the TUGT, subjects stand up from a 46 cm-tall chair, walk 3 m at their normal walking speed, bypass an obstacle, return, and sit down. NPWT requires participants to perform the same procedure as the TUGT. In NPWT, a 40 x 300 cm green mat with 24% Michelson contrast against the walking path to create a challenging environment, dividing the path into two 20 cm-wide narrow pathways to test mediolateral dynamic balance. The NPWT time will be measured. To add difficulty, the dual task of the serial subtraction will be added in the walking procedure.To achieve stable performance, each test will be repeated 3 times, and the results will be averaged to ensure consistency. The recording parameters for NPWT will include trial time, mistakes, cognitive performance, and dual-task cost.
Measured: The outcome will be assessed 6 times: before and after each stimulation session (tDCS, tACS, Sham session ) (each session length = 5 consecutive days). Therefore, there will be tDCS-pre, tDCS-post; tACS-pre, tACS-post; Sham-pre, Sham-post.
Secondary outcomes (4)
Balance performance - Mini-BESTest
The Mini-BESTest will be utilized to assess participants' balance through a series of 14 tasks that encompass both static and dynamic balance challenges, including activities such as sit-to-stand, walking with head turns, standing on one leg, and Time up and Go with a dual task. Each task is scored on a scale from 0 to 2, with higher scores reflecting superior balance abilities. To provide a comprehensive evaluation, we will include variations in task difficulty, enabling us to analyze how different levels of complexity influence balance performance. The total score from the Mini-BESTest will be examined to gauge participants' balance proficiency and to identify any improvements resulting from the intervention. All tasks will be administered in a standardized sequence, ensuring a systematic and reliable approach to balance assessment for all participants.
Measured: The outcome will be assessed 6 times: before and after each stimulation session (tDCS, tACS, Sham session ) (each session length = 5 consecutive days). Therefore, there will be tDCS-pre, tDCS-post; tACS-pre, tACS-post; Sham-pre, Sham-post.
Sensory Organization Test
The SOT provides a quantitative assessment of an individual's ability to utilize specific sensory cues to maintain stability during quiet stance. The protocol consists of six standardized conditions designed to systematically disrupt or isolate sensory information: (1) eyes open, firm surface; (2) eyes closed, firm surface; (3) sway-referenced vision, firm surface; (4) eyes open, sway-referenced surface; (5) eyes closed, sway-referenced surface; and (6) sway-referenced vision and surface. During the assessment, participants will be instructed to stand still with their feet shoulder-width apart for 20 seconds per trial. The primary outcome measures include the Composite Equilibrium Score, representing a weighted average of postural stability across all conditions, and Sensory Analysis Ratios, which are calculated to pinpoint specific impairments in the visual, somatosensory, and vestibular systems.
Measured: The outcome will be assessed 6 times: before and after each stimulation session (tDCS, tACS, Sham session ) (each session length = 5 consecutive days). Therefore, there will be tDCS-pre, tDCS-post; tACS-pre, tACS-post; Sham-pre, Sham-post.
Visual cognitive function-Useful Field of View test
The UFOV test will include three conditions:
- Stimulus Identification: A central target will be displayed on the screen for 60 frames, before being masked by a 'white noise' screen. The display duration will be adjusted using a 3-up/1-down adaptive staircase procedure to determine the threshold, with testing concluding after eight reversals or seventy-two total trials.
- Divided Attention: Both a central and a peripheral target will be displayed simultaneously, the latter appearing randomly at one of eight meridian locations (0°, 45°, 90°, 135°, 180°, 225°, 270°, 315°, 360°) at 20° from the center. The presentation duration will be adjusted using the algorithm as in test 1 to reach a threshold.
- Selective Attention: This condition will include a central target, a peripheral target, and additional peripheral distractors. The distractors will subtend the same visual angle as the peripheral target. Apart from the introduction of distractors, the procedure is the same as for test 2.
Measured: The outcome will be assessed 6 times: before and after each stimulation session (tDCS, tACS, Sham session ) (each session length = 5 consecutive days). Therefore, there will be tDCS-pre, tDCS-post; tACS-pre, tACS-post; Sham-pre, Sham-post.
Visual cognitive function-reaction time test
The total Reaction Time Test will be divided into two parts. The first part will involve a simple reaction assessment, utilizing Python software to create the stimulus.
Participants will be instructed to respond to a stimulus shown in the center of the screen. The second part of the test will involve a choice reaction test, in which four squares will be arranged horizontally on the screen. The stimulus will appear randomly in one of the squares, and the participants will be guided to react to the position as quickly as possible. For the first part, the corresponding time to the stimulus will be recorded. For the second part, the reaction time to the stimulus and the task accuracy will be recorded. Each part will be repeated 3 times to get the average score.
Measured: The outcome will be assessed 6 times: before and after each stimulation session (tDCS, tACS, Sham session ) (each session length = 5 consecutive days). Therefore, there will be tDCS-pre, tDCS-post; tACS-pre, tACS-post; Sham-pre, Sham-post.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Aug 2026
- Study start1 Jul 2026
- Primary completion1 Nov 2029 (estimated)
- Study completion1 Nov 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- More trials run by The Hong Kong Polytechnic UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Hong Kong Polytechnic University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Allen MY Cheong, The Hong Kong Polytechnic University
- Investigators
- Allen Ming yan Cheong, PhD, Principal investigator, The Hong Kong Polytechnic University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07771699
- Sponsor's protocol ID
- HSEARS20250611004
- Status last verified
- Aug 2026
- First submitted
- 28 Jul 2026
- Last updated
- 18 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD that underlie results in publication will be available upon reasonable request to the research team
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cross-modal Neuromodulation to Improve Balance and Cognition in Older Adults With Glaucoma: A Randomized Trial of Cerebellar Transcranial Electrical Stimulation
- ClinicalTrials.gov ID
- NCT07771699
- Acronym / sponsor ID
- HSEARS20250611004
- Conditions
- Glaucoma
- Keywords
- balance, glaucoma, visual attention, transcranial electrical stimulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- The Hong Kong Polytechnic UniversityUniversity, hospital or other
- Study start
- 1 Jul 2026 (actual)
- Primary completion
- 1 Nov 2029 (estimated)
- Study completion
- 1 Nov 2029 (estimated)
- First posted
- 18 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to use different tES techniques to constantly stimulate the cerebellum in older glaucoma patients. The main questions aim to answer :
- If the different types of tES targeting the cerebellum can modulate glaucoma patients' balance function and visual-cognitive function?
- Which tES techniques among the two types can benefit most?
Participants will be required to receive the stimulation 15 times (3 sessions, 5 continuous days/session, 1-week interval between each session), and complete the balance and visual-cognitive function outcome measurements before and after each session.
Detailed description
Previous research on tES has primarily focused on the effects of different brain cortex stimulation on balance and visual cognitive functions in healthy adults. However, there is a scarcity of research examining the combined effects of these techniques on the cerebellum in visually impaired adults, especially those with glaucoma. Given the cerebellum's crucial role in maintaining balance and cognitive function in glaucoma patients, as evidenced by the latest research, it is essential to determine whether non-invasive cerebellar stimulation can simultaneously improve balance and visual cognitive functions in these patients. Meanwhile, most previous studies only focused on the short-term effects of stimulation, while potential long-term benefits remained unexplored. Our study aims to investigate the long-term effects of two types of tES stimulation on the cerebellum in adults with glaucoma. This research not only aims to fill existing gaps in the literature but also has the potential to develop new intervention strategies to improve functioning in older adults, ultimately enhancing their quality of life.
This study employs a within-subject, sham-controlled, cross-over design. The participants will receive constant tDCS, tACS, and sham stimulation in counterbalanced order. The participants will have three sessions (each session will include five consecutive training sessions) with outcome measurements at six time points. These assessments consist of a baseline test (T1), a test after completing the first session (T2), a test after the first interval week (T3), a test after completing the second session (T4), a test after the second interval week (T5), and a test after completing the third session (T6). The total time will be five weeks.
The outcome measurements will include dynamic balance tests: narrow path walking test and miniBEST test; static balance test: Sensory Organization Test; and two visual cognitive function tests: Reaction Time Test and the Useful Field of View test.
For statistical analysis, IBM SPSS Statistics version 23.0 will be utilized. The Shapiro-Wilk test will be employed to assess the normality of the data distribution. For skewed numerical data, the appropriate transformations will be used to make the data meet the normality assumption. The differences in baseline performance among tACS, tDCS, and sham stimulation were analyzed using repeated-measures ANOVA. To compare the differences between changes in primary and secondary outcomes among baseline and post-intervention time points, the repeated-measures ANOVA will be performed with interventions (tACS, tDCS, and sham) as a within-group factor. Changes in the values will be calculated by subtracting baseline values from the post-intervention values. Paired t-statistics will be obtained to compare the changes in outcome data (subtract baseline from post-intervention) between the interventions (tACS versus tDCS, tACS versus sham, and tDCS versus sham). Post-hoc pairwise comparisons will be performed using Bonferroni corrections. The level of statistical significance is set at p < 0.05.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| tDCS | Experimental | Other: transcranial electrial stimulationThe tDCS stimulation session will be performed over five consecutive days. The tDCS protocol used in this study will involve the application of a low direct current of 2 mA for 20 minutes using a Nurostym tES device (Neuro Device Group SA, Poland). It begins with a 30-second ramp-up period and employs two 5 cm × 5 cm electrodes that are housed in saline-soaked sponges. The anode and the cathode electrodes will be placed bilaterally over the cerebellum (1 cm below the inion of the occipital bone) and the right shoulder, respectively. This electrode montage is based on previous studies and is designed to target cerebellar regions implicated in balance and motor control. |
| tACS | Experimental | Other: transcranial electrial stimulationThe tACS stimulation session will be five consecutive days. tACS protocol used in the study will be delivered using the Neurostym tES device (Neuro Device Group SA, Poland) with two 5 × 5 cm electrodes. The anode and the cathode electrodes will be placed bilaterally over the cerebellum (1 cm below the inion of the occipital bone) and the right shoulder, respectively. The tACS will be administered at a current of 2 mA with a stimulation frequency of 50 Hz. There will be a 30-second ramp-up and ramp-down period to minimize discomfort at the onset and offset of stimulation. |
| Sham | Sham comparator | Other: transcranial electrial stimulationThe sham protocol will mimic the same electrode placement as the other experimental group setting to maintain blinding. During sham stimulation, the stimulator will deliver 2 mA current for the first 30 seconds, after which the current will be turned off for the remainder of the session. To further enhance blinding, the current will be reactivated at 2 mA for the final 30 seconds of the stimulation and then gradually taper off thereafter. The total duration of the sham stimulation will match that of the active stimulation protocols (20 minutes). Each stimulation session will be five consecutive days. |
Who may qualify
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age over 55 years old;
- Diagnosis of primary open-angle or normal-tension glaucoma with relative scotoma in both eyes;
- Humphrey Field Analyzer visual field loss (mean deviation of ≤- 6 dB) using the 24-2 testing protocol for both eyes;
- Best-corrected distance visual acuity of 6/12 (equivalent to 0.3 logMAR) or better;
- Cognitive functional score of 22 or above in the Montreal Cognitive Assessment -Hong Kong version (HK-MoCA).
Key exclusion criteria (3 listed)
- Have musculoskeletal disorders or neurological diseases that can affect the balance or nervous system.
- Ocular diseases other than glaucoma (e.g., age-related macular degeneration, diabetic retinopathy, moderate to severe cataract) or severe hearing impairment (to ensure that participants can hear the instructions clearly during assessments and training)
- Have any contraindications for tES
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| transcranial electrial stimulationThis intervention is uniquely designed to enhance balance function in patients with glaucoma using non-invasive cerebellar Transcranial Electrical Stimulation (tES), encompassing both transcranial Direct Current Stimulation (tDCS) and transcranial Alternating Current Stimulation (tACS). Glaucoma-induced visual field loss disrupts the visual feedback critical for postural control, forcing patients to rely heavily on sensory re-weighting (integrating vestibular and proprioceptive inputs). The cerebellum is the central hub for this multi-sensory integration and motor adaptation. By modulating cerebellar excitability and neural oscillations, this intervention aims to facilitate sensory re-weighting, optimize vestibular-ocular/spinal reflexes, and ultimately improve dynamic and static balance. | Other | Sham, tACS, tDCS |
Primary outcome
Dynamic Balance Performance-The dual task Narrow Path Walking Test
Time frame: The outcome will be assessed 6 times: before and after each stimulation session (tDCS, tACS, Sham session ) (each session length = 5 consecutive days). Therefore, there will be tDCS-pre, tDCS-post; tACS-pre, tACS-post; Sham-pre, Sham-post.
The Narrow Path Walking Test (NPWT) is a modified version of the Time Up and Go Test (TUGT) that assesses dynamic balance function during gait in a more challenging environment. In the TUGT, subjects stand up from a 46 cm-tall chair, walk 3 m at their normal walking speed, bypass an obstacle, return, and sit down. NPWT requires participants to perform the same procedure as the TUGT. In NPWT, a 40 x 300 cm green mat with 24% Michelson contrast against the walking path to create a challenging environment, dividing the path into two 20 cm-wide narrow pathways to test mediolateral dynamic balance. The NPWT time will be measured. To add difficulty, the dual task of the serial subtraction will be added in the walking procedure.To achieve stable performance, each test will be repeated 3 times, and the results will be averaged to ensure consistency. The recording parameters for NPWT will include trial time, mistakes, cognitive performance, and dual-task cost.
4 secondary outcomes
Balance performance - Mini-BESTest
Time frame: The outcome will be assessed 6 times: before and after each stimulation session (tDCS, tACS, Sham session ) (each session length = 5 consecutive days). Therefore, there will be tDCS-pre, tDCS-post; tACS-pre, tACS-post; Sham-pre, Sham-post.
Sensory Organization Test
Time frame: The outcome will be assessed 6 times: before and after each stimulation session (tDCS, tACS, Sham session ) (each session length = 5 consecutive days). Therefore, there will be tDCS-pre, tDCS-post; tACS-pre, tACS-post; Sham-pre, Sham-post.
Visual cognitive function-Useful Field of View test
Time frame: The outcome will be assessed 6 times: before and after each stimulation session (tDCS, tACS, Sham session ) (each session length = 5 consecutive days). Therefore, there will be tDCS-pre, tDCS-post; tACS-pre, tACS-post; Sham-pre, Sham-post.
Visual cognitive function-reaction time test
Time frame: The outcome will be assessed 6 times: before and after each stimulation session (tDCS, tACS, Sham session ) (each session length = 5 consecutive days). Therefore, there will be tDCS-pre, tDCS-post; tACS-pre, tACS-post; Sham-pre, Sham-post.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
- Individual participant dataSharing planned: Yes. IPD that underlie results in publication will be available upon reasonable request to the research team
Related trials for Glaucoma
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Not yet recruiting
AI-Assisted vs Conventional Teleglaucoma Referral
Glaucoma
Recruiting
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Recruiting
Automated Applanation Tonometry - Updated
Glaucoma, Glaucoma, Suspect
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Allen Ming yan Cheong, PhD principal investigator
The Hong Kong Polytechnic University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing transcranial electrial stimulation in people with Glaucoma, run by The Hong Kong Polytechnic University at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yihong PENG, Phd student (+852-53937970, 22117438r@connect.polyu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dynamic Balance Performance-The dual task Narrow Path Walking Test (time frame: The outcome will be assessed 6 times: before and after each stimulation session (tDCS, tACS, Sham session ) (each session length = 5 consecutive days). Therefore, there will be tDCS-pre, tDCS-post; tACS-pre, tACS-post; Sham-pre, Sham-post.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.